BioStem Technologies (OTCMKTS:BSEM) Stock Price Up 2.3% – Time to Buy?

BioStem Technologies, Inc. (OTCMKTS:BSEM) shot up 2.3% during mid-day trading on Tuesday . The company traded as high as $4.04 and last traded at $3.98. Approximately 95,602 shares changed hands during trading, an increase of 183% from the average session volume of 33,738 shares. The stock had previously closed at $3.89.

Wall Street Analyst Weigh In

Separately, HC Wainwright started coverage on shares of BioStem Technologies in a report on Wednesday, May 6th. They issued a “buy” rating and a $9.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $9.00.

BioStem Technologies Stock Down 2.4%

The company has a market cap of $68.36 million, a PE ratio of -3.44 and a beta of 0.11. The company has a 50-day moving average of $3.84 and a 200-day moving average of $4.72.

BioStem Technologies (OTCMKTS:BSEM) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.24). The company had revenue of $6.14 million during the quarter, compared to analyst estimates of $5.70 million. As a group, equities analysts predict that BioStem Technologies, Inc. will post -1.95 EPS for the current year.

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.